CIK 0002096997 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Kailera Therapeutics, Inc.
Sign in to watch- Ticker
- KLRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 508-440-9475
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-07 | Nicholson Nur Chief Technology Officer | Grant or award · Stock Option (right to buy) | +220,000 | 220,000 | ||
| 2026-07-06 | Tregoning Kathleen See Remarks | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2026-06-09 | Renaud Ronald C JR CEO & President | Option exercise | +38,094 | $5.25 | $200K | 38,094 |
| 2026-06-09 | Renaud Ronald C JR CEO & President | Option exercise · Stock Option (right to buy) | −38,094 | 817,826 | ||
| 2026-04-20 | RTW INVESTMENTS, LP 10% owner | Conversion | +10,276,820 | 10,276,820 | ||
| 2026-04-20 | RTW INVESTMENTS, LP 10% owner | Purchase | +500,000 | $16.00 | $8.0M | 10,776,820 |
| 2026-04-20 | RTW INVESTMENTS, LP 10% owner | Conversion · Series A Preferred Stock | −8,250,000 | 0 | ||
| 2026-04-20 | RTW INVESTMENTS, LP 10% owner | Conversion · Series B Preferred Stock | −2,026,820 | 0 | ||
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Conversion | +9,477,719 | 9,477,719 | ||
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Conversion | +2,034,133 | 2,034,133 | ||
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Conversion · Series A-2 convertible preferred stock | −4,968,789 | 0 | ||
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Conversion · Series A-2 convertible non-voting preferred stock | −708,814 | 0 | ||
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC 10% owner | Conversion | +17,857,143 | 17,857,143 | ||
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC 10% owner | Purchase | +8,398,438 | $16.00 | $134.4M | 26,255,581 |
| 2026-04-20 | BAIN CAPITAL INVESTORS LLC 10% owner | Conversion · Series B Preferred Stock | −17,857,143 | 0 | ||
| 2026-04-20 | Koppel Adam Director | Conversion | +16,875,000 | 16,875,000 | ||
| 2026-04-20 | Koppel Adam Director | Conversion | +4,145,768 | 21,020,768 | ||
| 2026-04-20 | Koppel Adam Director | Purchase | +1,562,500 | $16.00 | $25.0M | 22,583,268 |
| 2026-04-20 | Koppel Adam Director | Conversion · Series A-1 Preferred Stock | −16,875,000 | 0 | ||
| 2026-04-20 | Koppel Adam Director | Conversion · Series B Preferred Stock | −4,145,768 | 0 |
Page 1 of 3 · 48 trades